Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of cardiovascular events is partly explained by plasma levels of low-density lipoprotein cholesterol (LDL-C). This study aimed to estimate individual benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in CAD patients already treated with high-dose statin. Methods Individual lifetime benefit was estimated in months gain free of stroke or myocardial infarction (MI) until age 80 years. Predictions were based on two competing risk models developed in data from 4853 patients with CAD originating from the atorvastatin 80 mg arm of the Treating to New Targets (TNT) trial. The relative effect of PCSK9 inhibition was added to the mo...
Dyslipidemia is a relatively common cardiovascular risk factor in the general population, particular...
Genetic, experimental and clinical studies have consistently confirmed that inhibition of proprotein...
Background As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enteri...
Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of car...
Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of car...
OBJECTIVE: In statin-treated patients with stable coronary artery disease (CAD), residual risk of ca...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
BACKGROUND: As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enter...
Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse...
BACKGROUND: As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enter...
Objective Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Man...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
Abstract The status of low-density lipoprotein (LDL) cholesterol is strong as an essential cause of ...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
Dyslipidemia is a relatively common cardiovascular risk factor in the general population, particular...
Genetic, experimental and clinical studies have consistently confirmed that inhibition of proprotein...
Background As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enteri...
Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of car...
Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of car...
OBJECTIVE: In statin-treated patients with stable coronary artery disease (CAD), residual risk of ca...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for m...
BACKGROUND: As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enter...
Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse...
BACKGROUND: As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enter...
Objective Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Man...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
Abstract The status of low-density lipoprotein (LDL) cholesterol is strong as an essential cause of ...
International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients a...
Dyslipidemia is a relatively common cardiovascular risk factor in the general population, particular...
Genetic, experimental and clinical studies have consistently confirmed that inhibition of proprotein...
Background As proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies are enteri...